Canada approved a generic semaglutide product for sale, creating what the government described as the first G7 pathway for generic competition to Novo Nordisk’s Wegovy/Ozempic. The generic, produced by Dr. Reddy’s Laboratories, is prescription-only and arrives as policy makers signal potential review of additional generic alternatives. The approval intensifies competition not only in injectable semaglutide but also across the broader oral GLP-1 pipeline, where Eli Lilly has been developing oral candidates. The development comes as semaglutide patent timelines have already opened in some jurisdictions, supporting rapid entry of additional generics. For biotech and pharma, generic approval is a direct test of pricing assumptions for GLP-1s and could pressure commercial models built on high list prices in major markets. The Canadian government’s consideration of further generic options suggests the semaglutide pricing debate is entering a new regulatory phase rather than remaining confined to patent litigation outcomes.